Text Size

Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens

This study has been completed.
Sponsor:
Collaborator:
Anonymous
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177333
First received: September 12, 2005
Last updated: October 20, 2008
Last verified: October 2008
History of Changes
  Purpose

This is a randomized double-blind, controlled trial comparing two regimens of pre-abortion doxycycline. The aims of the study are to determine the serum levels of doxycycline when administered pre-operatively 4 hours or approximately 18 hours before a dilation and evacuation (D & E) abortion. The hypotheses being tested are that subjects who receive doxycycline with food the night before an abortion will have adequate serum levels, but less nausea and vomiting compared to women who take the doxycycline on an empty stomach on the morning of the abortion. Subjects will either take 200mg doxycycline on the night before and 2 caps placebo with a sip of water on the morning of surgery or 2 caps placebo the night before and 200mg doxycycline on the morning of surgery with a sip of water. All capsules will look identical. Diaries, questionnaires and a 10cc sample of blood for doxycycline levels will be collected from the subjects at the time of surgery.


Condition Intervention Phase
Abortion, Induced
Vomiting
 Drug: Doxycycline
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • doxycycline side effects [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • nausea [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • vomiting [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • other side effects [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: September 2005
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Detailed Description:

This is a randomized double-blind, controlled trial comparing two regimens of pre-abortion doxycycline. The aims of the study are to determine the serum levels of doxycycline when administered pre-operatively 4 hours or approximately 18 hours before a dilation and evacuation (D & E) abortion. The hypotheses being tested are that subjects who receive doxycycline with food the night before an abortion will have adequate serum levels, but less nausea and vomiting compared to women who take the doxycycline on an empty stomach on the morning of the abortion. Subjects will either take 200mg doxycycline on the night before and 2 caps placebo with a sip of water on the morning of surgery or 2 caps placebo the night before and 200mg doxycycline on the morning of surgery with a sip of water. All capsules will look identical. Diaries, questionnaires and a 10cc sample of blood for doxycycline levels will be collected from the subjects at the time of surgery.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Gestational age 15-23 weeks by ultrasound.
  2. Willing and able to sign an informed consent.
  3. Placement of cervical dilators. Dilators must be placed before giving any subject doxycycline in order to ensure that all subjects who receive doxycycline will have an abortion.
  4. Willing to comply with the study protocol.
  5. Age at enrollment of 18 years or more.

Exclusion Criteria:

  1. Need for an urgent D & E. Indications for this include ruptured membranes, advanced cervical dilation, infection, and fetal demise.
  2. Allergy to doxycycline or any tetracycline
  3. Exposure to or treatment for gonorrhea or chlamydia within the past 90 days.
  4. Current or recent (within the past week) use of any other antibiotic.
  5. Prior cardiac valve surgery or cardiac valve replacement. These patients should all receive alternative antibiotics for endocarditis prophylaxis.
  6. Active use of alcohol, heroin, or cocaine. Active use of alcohol will be defined as more than 2 drinks per day. Any use of heroin or cocaine will be considered exclusionary.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00177333

Locations
United States, Pennsylvania
Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Anonymous
Investigators
Principal Investigator: M Reeves, MD University of Pittsburgh
  More Information

Additional Information:
University of Pittsburgh Center for Family Planning Research website  This link exits the ClinicalTrials.gov site

No publications provided by University of Pittsburgh

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Matthew Reeves, MD, MPH, University of Pittssburgh
ClinicalTrials.gov Identifier: NCT00177333     History of Changes
Other Study ID Numbers: pittirb0504092
Study First Received: September 12, 2005
Last Updated: October 20, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
Abortion, Induced
Doxycycline
Antibiotic Prophylaxis
Vomiting
Abortion, Therapeutic

Additional relevant MeSH terms:
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Doxycycline
Doxycycline hyclate
Anti-Bacterial Agents
 Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents

ClinicalTrials.gov processed this record on June 17, 2013